Issues related to the FDA and Health and Human Services pertaining to CBD policies; Issues related to the regulation of intoxicating hemp.
2025 · 4th Quarter (Oct 1 - Dec 31)
JAZZ PHARMACEUTICALS
Filed by TIBER CREEK GROUP.
Open official filingSource-reported fields
Filing overview
- Type
- 4th Quarter - Report
- Posted
- Jan 17, 2026
- Income
- $50,000.00
- Expenses
- Not reported
- Registrant
- TIBER CREEK GROUP
- Client
- JAZZ PHARMACEUTICALS
- Filing UUID
- cf034883-9666-4315-b134-ea79810fbcef
- Termination date
- Not reported
Literal source text
Lobbying issues and bill citations
Issues related to cannabis research; Issues related to the FDA; Issues related to cannabis research at Health and Human Services.
Issues related to FDA enforcement of non-FDA approved, cannabis derived CBD products in H.R. 4121 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026; Issues related to the Ag/FDA amendment - technical correction to hemp in H.R. 4121 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026; Issues related to intoxicating hemp products.
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.